Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 19

1.

Proof of Principle for Local Delivery of a c-Met Inhibitor.

Li H, Kadiyala I, Briggs M, Shawgo R, Reda K, Patel R, Tanner K, Berlioz-Seux F, Furey B, Hurter P, Boucher DM.

J Pharm Sci. 2018 Mar;107(3):856-862. doi: 10.1016/j.xphs.2017.10.025. Epub 2017 Oct 26.

PMID:
29107043
2.

Targeting the MAPK Signaling Pathway in Cancer: Promising Preclinical Activity with the Novel Selective ERK1/2 Inhibitor BVD-523 (Ulixertinib).

Germann UA, Furey BF, Markland W, Hoover RR, Aronov AM, Roix JJ, Hale M, Boucher DM, Sorrell DA, Martinez-Botella G, Fitzgibbon M, Shapiro P, Wick MJ, Samadani R, Meshaw K, Groover A, DeCrescenzo G, Namchuk M, Emery CM, Saha S, Welsch DJ.

Mol Cancer Ther. 2017 Nov;16(11):2351-2363. doi: 10.1158/1535-7163.MCT-17-0456. Epub 2017 Sep 22.

3.

Metabolic response of lung cancer cells to radiation in a paper-based 3D cell culture system.

Simon KA, Mosadegh B, Minn KT, Lockett MR, Mohammady MR, Boucher DM, Hall AB, Hillier SM, Udagawa T, Eustace BK, Whitesides GM.

Biomaterials. 2016 Jul;95:47-59. doi: 10.1016/j.biomaterials.2016.03.002. Epub 2016 Mar 3.

PMID:
27116031
4.

A paper-based invasion assay: assessing chemotaxis of cancer cells in gradients of oxygen.

Mosadegh B, Lockett MR, Minn KT, Simon KA, Gilbert K, Hillier S, Newsome D, Li H, Hall AB, Boucher DM, Eustace BK, Whitesides GM.

Biomaterials. 2015 Jun;52:262-71. doi: 10.1016/j.biomaterials.2015.02.012. Epub 2015 Feb 28.

PMID:
25818432
5.

Potentiation of tumor responses to DNA damaging therapy by the selective ATR inhibitor VX-970.

Hall AB, Newsome D, Wang Y, Boucher DM, Eustace B, Gu Y, Hare B, Johnson MA, Milton S, Murphy CE, Takemoto D, Tolman C, Wood M, Charlton P, Charrier JD, Furey B, Golec J, Reaper PM, Pollard JR.

Oncotarget. 2014 Jul 30;5(14):5674-85.

6.

Factors influencing development of new therapeutics for oncology.

Winquist RJ, Boucher DM.

Curr Opin Pharmacol. 2010 Aug;10(4):353-5. doi: 10.1016/j.coph.2010.06.011. Epub 2010 Jul 14. No abstract available.

PMID:
20634136
7.

Cancer stem cells as the relevant biomass for drug discovery.

Winquist RJ, Furey BF, Boucher DM.

Curr Opin Pharmacol. 2010 Aug;10(4):385-90. doi: 10.1016/j.coph.2010.06.008. Epub 2010 Jul 12. Review.

PMID:
20630801
8.

Targeting cancer stem cells for more effective therapies: Taking out cancer's locomotive engine.

Winquist RJ, Boucher DM, Wood M, Furey BF.

Biochem Pharmacol. 2009 Aug 15;78(4):326-34. doi: 10.1016/j.bcp.2009.03.020. Epub 2009 Apr 1.

PMID:
19539800
9.

Functions of MAP kinases: insights from gene-targeting studies.

Kuida K, Boucher DM.

J Biochem. 2004 Jun;135(6):653-6. Review.

10.

Extracellular signal-regulated kinase 2 is necessary for mesoderm differentiation.

Yao Y, Li W, Wu J, Germann UA, Su MS, Kuida K, Boucher DM.

Proc Natl Acad Sci U S A. 2003 Oct 28;100(22):12759-64. Epub 2003 Oct 17.

11.
12.

Erk5 null mice display multiple extraembryonic vascular and embryonic cardiovascular defects.

Regan CP, Li W, Boucher DM, Spatz S, Su MS, Kuida K.

Proc Natl Acad Sci U S A. 2002 Jul 9;99(14):9248-53. Epub 2002 Jul 1.

13.

goosecoid expression represses Brachyury in embryonic stem cells and affects craniofacial development in chimeric mice.

Boucher DM, Schäffer M, Deissler K, Moore CA, Gold JD, Burdsal CA, Meneses JJ, Pedersen RA, Blum M.

Int J Dev Biol. 2000 Apr;44(3):279-88.

14.

Induction and differentiation of extra-embryonic mesoderm in the mouse.

Boucher DM, Pedersen RA.

Reprod Fertil Dev. 1996;8(4):765-77. Review.

PMID:
8870097
16.

Comparison of blood gas and electrolyte test results from the Gem-Stat and CDI-300 versus a conventional laboratory analyzer.

Walton HG, Duvall TB, Van den Hout J, Boucher DM.

J Extra Corpor Technol. 1993;25(2):53-7.

PMID:
10171685
17.

Reduction of canine myocardial infarct size by CI-959, an inhibitor of inflammatory cell activation.

Burke SE, Wright CD, Potoczak RE, Boucher DM, Dodd GD, Taylor DG Jr, Kaplan HR.

J Cardiovasc Pharmacol. 1992 Oct;20(4):619-29.

PMID:
1280719
18.

Antihypertensive profile of the angiotensin-converting enzyme inhibitors CI-906 and CI-907.

Ryan MJ, Boucher DM, Cohen DM, Olszewski BJ, Singer RM, Smith RD, Kaplan HR.

Fed Proc. 1984 Apr;43(5):1330-2.

PMID:
6323224
19.

Antihypertensive effects of CI-907 (indolapril): a novel nonsulfhydryl angiotensin converting enzyme inhibitor.

Ryan MJ, Boucher DM, Cohen DM, Essenburg AD, Major TC, Mertz TE, Olszewski BJ, Randolph AE, Singer RM, Kaplan HR.

J Pharmacol Exp Ther. 1984 Feb;228(2):312-8.

PMID:
6319675

Supplemental Content

Loading ...
Support Center